HOUSTON – (May 15, 2023) – Researchers at Baylor College of Medicine/Texas Children’s Cancer Center and collaborating institutions report interim results from a first-in-human phase 1 clinical trial ...
Company’s lead program, GRI-0621, has demonstrated ability to inhibit the activity of type I invariant NKT (iNKT) cells early in the inflammatory cascade to prevent cytokine release, cellular ...
TOKYO & MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and ...
GRI Bio, Inc., a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic, and autoimmune diseases, announced that the European Patent Office has ...
A team of scientists at the University of California, Los Angeles (UCLA) have developed a groundbreaking cell-based ...
NEW YORK--(BUSINESS WIRE)--Investigators from Baylor College of Medicine (BCM) in collaboration with Immunai have published results from a clinical study in which Immunai’s technology helped identify ...
UCLA researchers have developed a new kind of immunotherapy that harnesses the body’s immune system to fight cancer more effectively. The innovative cell therapy uses specially engineered immune cells ...
Most new cell therapies work well on blood cancers but not on solid tumors like pancreatic cancer. Pancreatic tumors are ...
Autologous chimeric antigen receptor (CAR) T-cell therapy has been one of the most recent successes in cancer treatment, but limitations, such as manufacturing, costs or antigen escape in therapies ...
Researchers at Baylor College of Medicine/Texas Children's Cancer Center and collaborating institutions report interim results from a first-in-human phase 1 clinical trial evaluating the safety, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback